CA2279577A1 - Traitement de l'incontinence urinaire par des techniques de therapie genique - Google Patents

Traitement de l'incontinence urinaire par des techniques de therapie genique Download PDF

Info

Publication number
CA2279577A1
CA2279577A1 CA002279577A CA2279577A CA2279577A1 CA 2279577 A1 CA2279577 A1 CA 2279577A1 CA 002279577 A CA002279577 A CA 002279577A CA 2279577 A CA2279577 A CA 2279577A CA 2279577 A1 CA2279577 A1 CA 2279577A1
Authority
CA
Canada
Prior art keywords
igf
gene
vector
expression
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002279577A
Other languages
English (en)
Inventor
Michael Coleman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urigen Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2279577A1 publication Critical patent/CA2279577A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention a trait en partie à des procédés destinés au traitement de l'incontinence urinaire par des techniques de thérapie génique. Les procédés prévoient l'apport et l'expression de facteurs de croissance ou de facteurs neurotrophiques à/dans des tissus de mammifères.
CA002279577A 1997-02-04 1998-02-04 Traitement de l'incontinence urinaire par des techniques de therapie genique Abandoned CA2279577A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3686297P 1997-02-04 1997-02-04
US60/036,862 1997-02-04
PCT/US1998/002051 WO1998033529A1 (fr) 1997-02-04 1998-02-04 Traitement de l'incontinence urinaire par des techniques de therapie genique

Publications (1)

Publication Number Publication Date
CA2279577A1 true CA2279577A1 (fr) 1998-08-06

Family

ID=21891070

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002279577A Abandoned CA2279577A1 (fr) 1997-02-04 1998-02-04 Traitement de l'incontinence urinaire par des techniques de therapie genique

Country Status (5)

Country Link
EP (1) EP0981378A1 (fr)
JP (1) JP2001511154A (fr)
AU (1) AU739224B2 (fr)
CA (1) CA2279577A1 (fr)
WO (1) WO1998033529A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271211B1 (en) 1997-02-13 2001-08-07 Albert Einstein College Of Medicine Of Yeshiva University Gene therapy for regulating penile smooth muscle tone
US6239117B1 (en) 1997-02-13 2001-05-29 Albert Einstein College Of Medicine Of Yeshiva University Gene therapy for regulating bladder smooth muscle tone
US7030096B1 (en) 1997-02-13 2006-04-18 Albert Einstein College Of Medicine Of Yeshiva University Method of enhancing relaxation of penile smooth muscle by introduction of DNA encoding maxi-K potassium channel protein
JP2002523380A (ja) * 1998-08-18 2002-07-30 イェシバ・ユニバーシティ 平滑筋細胞緊張調節用の遺伝子治療
FI991197A0 (fi) * 1999-05-27 1999-05-27 Mart Saarma Neurotrooppiset tekijät lantionalueen ääreishermoston toimintahäiriön hoitamisessa
AU2022262176A1 (en) * 2021-04-19 2023-11-02 Versameb Ag Method of treating lower urinary tract symptoms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071137A1 (fr) * 1991-07-10 1993-01-11 Clarence C. Lee Composition et methode pour la revitalisation du tissu cicatriciel
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems

Also Published As

Publication number Publication date
WO1998033529A1 (fr) 1998-08-06
AU6142798A (en) 1998-08-25
JP2001511154A (ja) 2001-08-07
AU739224B2 (en) 2001-10-04
EP0981378A1 (fr) 2000-03-01

Similar Documents

Publication Publication Date Title
US6423693B1 (en) Growth hormone releasing hormone expression system and methods of use, including use in animals
EP0943003B1 (fr) Systeme d'expression du facteur de croissance insulinoide i (igf-i) et ses methodes d'utilisation
US6147055A (en) Cancer treatment method utilizing plasmids suitable for IL-2 expression
AU660751B2 (en) Myogenic vector systems
AU1626899A (en) Compositions and methods for inducing gene expression
US20080207543A1 (en) Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
Alila et al. Expression of biologically active human insulin-like growth factor-I following intramuscular injection of a formulated plasmid in rats
US20180271942A1 (en) Use of the Insulin-Like-Growth Factor 1 Splice Variant MGF for the Prevention of Myocardial Damage
CA2279577A1 (fr) Traitement de l'incontinence urinaire par des techniques de therapie genique
Teshima-Kondo et al. Hyperglycemia upregulates translation of the fibroblast growth factor 2 mRNA in mouse aorta via internal ribosome entry site.
EP1218508B1 (fr) Séquences d'ADN pour accroître l'efficacité de l'alimentation et la vitesse de croissance des porcins
AU770982B2 (en) Insulin-like growth factor I (IGF-I) expression system and methods of use
AU5366298A (en) Insulin-like growth factor i (igf-i) expression system and methods of use
Goldspink Local and systemic regulation of muscle growth.
Daughaday Laron Z, Parks JS (eds): Lessons from Laron Syndrome (LS) 1966–1992. Pediatr Adolesc Endocrinol. Basel, Karger, 1993, vol 24, pp 338-345
EP2694114A1 (fr) Stimulateur spécifique d'un muscle squelettique

Legal Events

Date Code Title Description
FZDE Dead